Miller Global Investments LLC Invests $1.11 Million in Bristol Myers Squibb Company $BMY

Key Points

• Miller Global Investments LLC opened a new position in Bristol Myers Squibb, buying 20,650 shares worth approximately $1.11 million, equal to about 1.0% of its portfolio and its 25th largest holding.
• Analyst views are mixed: several firms raised targets or initiated coverage (Barclays and Piper Sandler at $75; Bank of America upgraded to Buy with a $61 target), but MarketBeat's consensus rating remains Hold with an average target of $61.41.
• BMY missed quarterly EPS estimates ($1.26 vs. $1.65) while revenue slightly exceeded expectations, set FY2026 guidance of $6.05–$6.35, and declared a quarterly dividend of $0.63 (annualized yield ~4.3%).

Miller Global Investments LLC bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 20,650 shares of the biopharmaceutical company's stock, valued at approximately $1,114,000. Bristol Myers Squibb accounts for about 1.0% of Miller Global Investments LLC's investment portfolio, making the stock its 25th largest holding.

Several other hedge funds have also modified their holdings of the stock. CVA Family Office LLC increased its stake in Bristol Myers Squibb by 2.6% in the 3rd quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company's stock worth $404,000 after purchasing an additional 223 shares in the last quarter. MSH Capital Advisors LLC lifted its stake in Bristol Myers Squibb by 2.9% during the third quarter. MSH Capital Advisors LLC now owns 8,034 shares of the biopharmaceutical company's stock valued at $362,000 after buying an additional 223 shares in the last quarter. Bell & Brown Wealth Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 0.5% in the third quarter. Bell & Brown Wealth Advisors LLC now owns 42,691 shares of the biopharmaceutical company's stock worth $1,925,000 after buying an additional 224 shares during the period. Addison Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 6.2% in the third quarter. Addison Advisors LLC now owns 3,972 shares of the biopharmaceutical company's stock worth $179,000 after buying an additional 232 shares during the period. Finally, Mccarter Private Wealth Services LLC increased its position in shares of Bristol Myers Squibb by 5.0% in the third quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company's stock worth $222,000 after acquiring an additional 235 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd. Citigroup boosted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a "neutral" rating in a research note on Friday, February 6th. Barclays initiated coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They issued an "overweight" rating and a $75.00 target price for the company. Bank of America upgraded Bristol Myers Squibb from a "neutral" rating to a "buy" rating and lifted their price target for the company from $52.00 to $61.00 in a report on Monday, December 15th. Finally, Piper Sandler reissued an "overweight" rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Bristol Myers Squibb presently has a consensus rating of "Hold" and an average target price of $61.41.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $58.17 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a fifty day simple moving average of $58.57 and a 200 day simple moving average of $51.74. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The company has a market cap of $118.46 billion, a P/E ratio of 16.86, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period last year, the business earned $1.67 EPS. The business's quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb's dividend payout ratio is 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.